Read by QxMD icon Read

Neoadjuvant chemotherapy bladder cancer

Mario I Fernández, Stephen B Williams, Daniel L Willis, Rebecca S Slack, Rian J Dickstein, Sahil Parikh, Edmund Chiong, Arlene O Siefker-Radtke, Charles C Guo, Bogdan A Czerniak, David J McConkey, Jay B Shah, Louis L Pisters, H Barton Grossman, Colin P N Dinney, Ashish M Kamat
OBJECTIVE: To analyze survival in clinically localized, surgically resectable micropapillary bladder cancer patients undergoing radical cystectomy with and without neoadjuvant chemotherapy and develop risk strata based on outcome data. PATIENTS AND METHODS: A review of our database identified 103 patients with surgically resectable (≤cT4acN0cM0) micropapillary bladder cancer who underwent radical cystectomy. Survival estimates were calculated using Kaplan-Meier method and compared using log-rank tests...
October 18, 2016: BJU International
Rafael Morales-Barrera, Cristina Suárez, Ana Martínez de Castro, Fabricio Racca, Claudia Valverde, Xavier Maldonado, Juan Maria Bastaros, Juan Morote, Joan Carles
Bladder cancer is one of the leading causes of death in Europe and the United States. About 25% of patients with bladder cancer have advanced disease (muscle-invasive or metastatic disease) at presentation and are candidates for systemic chemotherapy. In the setting of metastatic disease, use of cisplatin-based regimens improves survival. However, despite initial high response rates, the responses are typically not durable leading to recurrence and death in the vast majority of these patients with median overall survival of 15months and a 5-year survival rate of ⩽10%...
October 1, 2016: Cancer Treatment Reviews
Robert Rosenblatt, Markus Johansson, Farhood Alamdari, Alexander Sidiki, Benny Holmström, Johan Hansson, Janos Vasko, Per Marits, Susanne Gabrielsson, Katrine Riklund, Ola Winqvist, Amir Sherif
PURPOSE: To determine whether sentinel node detection (SNd) in muscle-invasive urothelial bladder cancer (MIBC) can be performed in patients undergoing neoadjuvant chemotherapy (NAC) and determine whether SNd is feasible in all pT stages, including pT0. BACKGROUND: Previous published series of SNd in MIBC have not included patients undergoing NAC, and systematic reports of pT0 patients w/wo NAC were absent. Translational immunological tumor research on MIBC focusing on SNd, in the era of NAC, requires technical feasibility...
October 13, 2016: World Journal of Urology
Isabel Heidegger, Gennadi Tulchiner, Georg Schäfer, Wolfgang Horninger, Renate Pichler
BACKGROUND: Small cell bladder cancer (SCBC) is an aggressive subtype accounting for less than 1 % of all bladder malignancies associated with rapid progression, early metastases formation and high mortality rates. CASE PRESENTATION: We present an unusual long term disease free survival of a 60 year-old man who was diagnosed with SCBC two and a half years ago. He underwent four cycles of cisplatin/etoposide chemotherapy as well as a prophylactic whole-brain radiotherapy followed by a radical cystoprostatectomy and ileal neobladder with extended pelvic lymphadenectomy...
October 13, 2016: European Journal of Medical Research
Oktay Üçer, Ali Can Albaz, Elif Atag, Aziz Karaoglu, Talha Muezzinoglu
PURPOSE: To investigate the proportion of neoadjuvant chemotherapy (NAC) use in patients with muscle invasive bladder cancer before radical cystectomy and the approach of urologists to this subject. MATERIALS AND METHODS: We invited 242 urologists during the 12th International Urooncology Congress in Turkey to answer a self-administered questionnaire. The questionnaire included questions related to radical cystectomy, lymph node dissection and neoadjuvant chemotherapy that had been performed in patients with muscle invasive bladder cancer by the urologist...
October 10, 2016: Urology Journal
Nuradh Joseph, Ananya Choudhury
No abstract text is available yet for this article.
November 1, 2016: International Journal of Radiation Oncology, Biology, Physics
Armin Soave, Sabine Riethdorf, Roland Dahlem, Gunhild von Amsberg, Sarah Minner, Lars Weisbach, Oliver Engel, Margit Fisch, Klaus Pantel, Michael Rink
To investigate outcomes of urothelial carcinoma of the bladder (UCB) patients treated with radical cystectomy (RC) according to the presence of circulating tumor cells (CTC) and the administration of adjuvant chemotherapy (AC). We prospectively enrolled 226 UCB patients treated with RC without neoadjuvant chemotherapy at our institution between 2007 and 2013. Blood samples were obtained from all patients preoperatively and analyzed for CTC using the CellSearch(®) system. Platinum-based AC was administered in 50 patients (27...
September 26, 2016: International Journal of Cancer. Journal International du Cancer
Thomas Vinotha, Thomas Anitha, Sebastian Ajit, Chandy Rachel, Peedicayil Abraham
INTRODUCTION: Patients referred with inadequately staged ovarian malignancies present a clinical dilemma. We report our experience with completion surgery in ovarian cancer. AIMS AND OBJECTIVES: To determine the benefits and risks of completion surgery in women with ovarian cancer who presented after having had inadequate primary surgery. METHODS: A retrospective case series of 30 women with ovarian cancer and one with fallopian tube cancer who had inadequate primary surgery underwent completion surgery at gynaecologic oncology unit in a tertiary level hospital in Tamil Nadu, India...
October 2016: Journal of Obstetrics and Gynaecology of India
Aaron Brant, Max Kates, Meera R Chappidi, Hiten D Patel, Nikolai A Sopko, George J Netto, Alex S Baras, Noah M Hahn, Phillip M Pierorazio, Trinity J Bivalacqua
PURPOSE: We estimated the proportion of patients who received neoadjuvant chemotherapy for muscle-invasive bladder cancer whose tumors were downstaged by transurethral resection. MATERIALS AND METHODS: We identified patients with cT2 N0 urothelial carcinoma who underwent cystectomy at our institution from 2005 to 2014-overall, 139 underwent transurethral resection without chemotherapy, and 146 underwent transurethral resection with chemotherapy. Pathologic response was defined as<pT2 N0...
September 14, 2016: Urologic Oncology
Evanguelos Xylinas, Melanie R Hassler, Dazhong Zhuang, Martin Krzywinski, Zeynep Erdem, Brian D Robinson, Olivier Elemento, Thomas Clozel, Shahrokh F Shariat
Bladder cancer is among the five most common cancers diagnosed in the Western world and causes significant mortality and morbidity rates in affected patients. Therapeutic options to treat the disease in advanced muscle-invasive bladder cancer (MIBC) include cystectomy and chemotherapy. Neoadjuvant cisplatin-based combination chemotherapy is effective in MIBC; however, it has not been widely adopted by the community. One reason is that many patients do not respond to neoadjuvant chemotherapy, and no biomarker currently exists to identify these patients...
September 2, 2016: Biomolecules
Q Alimi, B Peyronnet, S-F Kammerer-Jacquet, M Lefevre, B Gires, R Mathieu, L Tondut, S Vincendeau, A Manunta, N Rioux-Leclercq, F Guille, K Bensalah, G Verhoest
INTRODUCTION: The aim of this study was to report perioperative and oncological outcomes of robot-assisted radical cystectomy (RARC) in a single-center series and to evaluate the impact of the experience on perioperative outcomes. METHODS: Between March 2012 and January 2016, 41 patients underwent RARC associated with extended pelvic lymphadenectomy for muscle-invasive bladder cancer. All RARC included were performed by a single-surgeon in one center. Perioperative and oncological datas were collected prospectively...
September 2016: Progrès en Urologie
Sharon Amir, Nicola J Mabjeesh
Bladder cancer (BC) is generally divided into non-muscle-invasive BC (NMIBC) and muscle-invasive BC (MIBC). The standard treatment protocol for MIBC patients is radical cystectomy preceded by neoadjuvant chemotherapy (NAC). About one-half of the MIBC patients show a priori resistance to chemotherapy, and are therefore exposed to the risks of disease progression and toxicity from ineffective NAC. The discovery of microRNA (miRNA) regulation in tumorigenesis has provided new directions for the development of a new type of BC biomarkers...
September 2, 2016: Histology and Histopathology
Mari Ohtaka, Yusuke Hattori, Yohei Kumano, Yoko Maeda, Takuya Kondo, Taku Mochizuki, Takashi Kawahara, Jun-Ichi Teranishi, Yasuhide Miyoshi, Yasushi Yumura, Hiroji Uemura
Hyponatremia is one of the common electrolyte disorders associated with cisplatin (CDDP) administration. We report here two cases of hyponatremia associated with CDDP. Case 1 : A 75-year-old man with urothelial carcinoma of bladder (cT3N1M0) underwent neoadjuvant chemotherapy with CDDP and gemcitabine. He lost consciousness on the eighth day after the chemotherapy. Blood tests showed severe hyponatremia (Na 113 mEq/l), low plasma osmolality and high level of plasma vasopressin. Urine tests showed low osmolality...
July 2016: Hinyokika Kiyo. Acta Urologica Japonica
Hiromi Murasawa, Takuya Koie, Chikara Ohyama, Hayato Yamamoto, Atsushi Imai, Shingo Hatakeyama, Takahiro Yoneyama, Yasuhiro Hashimoto, Ikuya Iwabuchi, Masaru Ogasawara, Toshiaki Kawaguchi
BACKGROUND: There are currently no data supporting carboplatin-based regimens in muscle-invasive bladder cancer patients who are unsuitable for neoadjuvant cisplatin treatment. The aim of this study was to investigate the potential benefit of carboplatin-based regimens in patients with muscle-invasive bladder cancer who were unsuitable for cisplatin. METHODS: We focused on 171 patients ineligible for cisplatin, including 98 patients who received neoadjuvant gemcitabine and carboplatin (GCarbo) followed by immediate radical cystectomy (GCarbo cohort) and 73 patients who underwent radical cystectomy (RC alone cohort) at Hiroaki University or Aomori Prefectural Hospital...
August 17, 2016: International Journal of Clinical Oncology
Ding Xia, Weiwei Lou, Kar-Ming Fung, Cole L Wolley, Mahmoud M Suhail, Hsueh-Kung Lin
A 52-year-old Hispanic male presented with hematuria and was later diagnosed with a large invasive high-grade urothelial cell carcinoma (UCC) of the urinary bladder, but with ambiguous pT1/pT2 staging regarding musclaris propria invasion by UCC. The conventional treatment including radical cystoprostatectomy followed by neoadjuvant chemotherapy with or without radiation therapy was presented. The patient decided to delay the standard therapy until a later stage, but elected to go through transurethral resection of bladder tumor (TURBT) without Bacillus Calmette-Guérin instillation...
August 16, 2016: Integrative Cancer Therapies
Marco Moschini, Francesco Soria, Tobias Klatte, Gregory J Wirth, Mehmet Özsoy, Killian Gust, Alberto Briganti, Morgan Roupret, Martin Susani, Andrea Haitel, Shahrokh F Shariat
INTRODUCTION: The aim of this study was to validate the value of preoperative patient characteristics in prognosticating survival after radical cystectomy (RC) to guide treatment decisions regarding neoadjuvant systemic treatment. METHODS: We evaluated a single cohort of 449 consecutive patients treated with RC for bladder cancer. Patients treated with neoadjuvant therapy were excluded from the study cohort (n = 24). Patients were stratified based on preoperative characteristics into 2 risk groups...
July 22, 2016: Clinical Genitourinary Cancer
Thomas Longo, Kathleen F McGinley, Jennifer A Freedman, Wiguins Etienne, Yuan Wu, Alexander Sibley, Kouros Owzar, Jeremy Gresham, Christopher Moy, Stephen Szabo, Joel Greshock, Hui Zhou, Yuchen Bai, Brant A Inman
: We completed targeted exome sequencing of the tumors of 50 patients with pTis-pT4b bladder cancer. Mutations were categorized by type, stratified against previously identified cancer loci in the Catalogue of Somatic Mutations in Cancer and The Cancer Genome Atlas databases, and evaluated in pathway analysis and comutation plots. We analyzed mutation associations with receipt of neoadjuvant chemotherapy, nodal involvement, metastatic disease development, and survival. Compared with The Cancer Genome Atlas, we found higher mutation rates in genes encoding products involved in epigenetic regulation and cell cycle regulation...
August 9, 2016: European Urology
Yongxiu Yang, Tiansheng Qin, Wei Zhang, Qiyan Wu, Aihong Yang, Feixue Xu
OBJECTIVE: The study aimed to evaluate the clinical outcomes of laparoscopic nerve-sparing radical hysterectomy (LNRH) for bulky-stage cervical cancer (lesion ≥ 6 cm) after neoadjuvant chemotherapy (NAC). METHODS: This study prospective recruited patients with pathology-confirmed cervical cancer presenting as a bulky mass (lesion ≥ 6 cm). Subjects included patients who underwent laparoscopic radical surgery. They were assigned to one of two groups by surgical method: patients who underwent LNRH after NAC and patients who underwent classical laparoscopic radical hysterectomy (LRH) after NAC...
August 9, 2016: International Journal of Surgery
Gustaf Klinga, Amir Sherif
BACKGROUND AND OBJECTIVE: Neoadjuvant chemotherapy (NAC) can be associated with anemia, which can lead to more perioperative blood transfusions (PBT). Usage of PBT is associated with worse oncological outcomes. We evaluated the prevalence of preoperative anemia (PA) and the effect on hemoglobin levels depending on surgery timing after NAC. METHODS: A retrospective single-center study with 240 consecutive patients undergoing radical cystectomy (RC) between 2001 and 2014 for muscle-invasive urothelial carcinoma (MIBC)...
2016: SpringerPlus
R Leibowitz-Amit, A Israel, M Gal, E A Atenafu, Z Symon, O Portnoy, M Laufer, Z Dotan, J Ramon, D Avni, E Fridman, R Berger
AIMS: Platinum-based neoadjuvant chemotherapy (NAC) improves overall survival in muscle-invasive bladder cancer (MIBC). A pathological complete response (pCR) at radical cystectomy after NAC is associated with better overall survival, but there are no established predictive biomarkers of response to NAC in MIBC. The aim of this study was to find laboratory variables associated with pCR following NAC. MATERIALS AND METHODS: We carried out a retrospective review of MIBC patients treated with NAC followed by radical cystectomy at the Sheba Medical Center between 2005 and 2015...
August 4, 2016: Clinical Oncology: a Journal of the Royal College of Radiologists
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"